Medicine is a science of uncertainty and an art of probability.
After a day on the wards I pick the questions that came up and write the answer the way I would explain it at the bedside: what we used to do, what we do now, and the trial that changed it. There is no schedule. A new page appears when a day was worth writing down.
Short
One idea per card. Each topic opens with the single line to remember. Readable between patients.
Sourced
Each topic ends with the papers and labels the numbers came from, so you can check me.
Not a protocol
It does not replace the treatment plan, pharmacy, or current guidelines. Scenarios are altered for teaching and contain no patient information.
Tips
Nov 19, 2026
Nov 18, 2026
Nov 15, 2026
Nov 12, 2026
Nov 10, 2026
- Two lines low with low reticulocytes: what to order tonight, what to write, where people slip
- Pancytopenia in the critically ill: when it is no longer the sepsis
- Rectal cancer: mismatch repair first, Memorial versus AZUR-1, and watch and wait
- Bortezomib once or twice a week: speed versus nerves, and why the kidney changes the answer
Nov 5, 2026
Nov 4, 2026
- A clot with cancer in clinic: why edoxaban and rivaroxaban bleed more with gut and urinary tumors and apixaban does not, the platelet line, and why apixaban 2.5 mg waits until after 6 months
- Oral iron done right: hepcidin and alternate-day single doses, what blocks absorption, a high erythropoietin with low iron, and the 2-week check before switching to the vein
Nov 3, 2026
Oct 29, 2026
Oct 28, 2026
Oct 26, 2026
- p16-positive oropharyngeal cancer by AJCC Version 9: T3 or T4, the three N rulers, the stage groups, and a stage calculator
- KEYNOTE-689: who got in, what perioperative pembrolizumab did, and where it did not help
- Transfusion in pregnancy: why the hemoglobin is not the trigger, and the first hour of a postpartum hemorrhage
Oct 23, 2026
- A clot in pregnancy: what crosses the placenta, the dose, the delivery and the six weeks after, and where warfarin hurts the fetus
- Antiphospholipid syndrome: the 2023 classification criteria point by point, and why early miscarriages no longer qualify
- Antiphospholipid syndrome in practice: warfarin, aspirin and heparin by patient, and what the pregnancy loss trials showed
Oct 22, 2026
- Refractory immune thrombocytopenia: why the bone marrow comes before the thrombopoietin agonist, and what monocytosis on the flow report changes
- Squamous cell carcinoma of the scalp found late: where it drains, why the PET must include the vertex, and what PD-1 blockade delivers
- Small mediastinal nodes in a young adult with a cough: four doors, which one blood opens, and a PET to pick the node for the needle
Oct 21, 2026
- A lupus anticoagulant drawn on warfarin: why the result is unreadable, not negative, and what to send instead
- Low counts in cirrhosis: the spleen, the bottle and the stomach, when the marrow is needed, and two prescriptions to stop
- Three iron traps: a microcytic "anemia of kidney disease", a ferritin of 695 with a saturation of 5%, and an electrophoresis read while the iron was low
Oct 19, 2026
- PSA 340 after six months of nothing: no testosterone, no verdict; the fork between a lapsed hormone-sensitive patient and a castration-resistant one after docetaxel, and what each gets next
- Abiraterone and the three lutamides: where each acts, the trial behind every approval with its numbers, and how comorbidities choose the pill
- POEMS syndrome: a lambda clone with numb feet, swollen legs and painful breasts, where to look on the patient, what closes the diagnosis, how it differs from amyloid, and radiation or systemic therapy
Oct 18, 2026
Oct 17, 2026
Oct 15, 2026
- Pulmonary tumor thrombotic microangiopathy: the four findings that should make you say the name, how to confirm it without a lung biopsy, and what the survivors received
- Bilirubin that climbs while the transaminases fall: the expected tail of liver injury, Hy's law, and when it is a duct
- Hemoglobin electrophoresis after a transfusion: a mixed sample, iron deficiency hiding thalassemia trait, and the Mentzer index
- Anticoagulation while breastfeeding: heparin and warfarin yes, direct oral anticoagulants no, and how long
Oct 14, 2026
- Ifosfamide and the leaking tubule: recognizing Fanconi syndrome, the cumulative dose, and the order of electrolyte repletion
- Visceral crisis: the definition, what it is not, and the trial where targeted therapy beat chemotherapy in "aggressive" disease
- Cryoglobulins in angioimmunoblastic T-cell lymphoma: the three types, the complement pattern, and how to send the tube warm
- The confused myeloma patient: the list in order, why light chains rarely cause hyperviscosity, and what plasma exchange cannot do
Oct 13, 2026
- Locally advanced rectal cancer: mismatch repair first, capecitabine dose during radiation, and total neoadjuvant therapy
- Anterior mediastinal mass in a young adult: serum markers, no steroids before tissue, biopsy safety
- Reading the chemistry panel in the first week of chemotherapy: three traps
- The drugs that raise platelets, and the new trial in chemotherapy-induced thrombocytopenia
Oct 12, 2026
- Antiphospholipid syndrome: when to suspect it, the criteria, who gets warfarin, and pregnancy
- A patient with anemia: reticulocytes first, then cell size, and how to treat each
- Erythropoietin in cancer, kidney disease and heart failure: who can receive it, and why heart failure gets iron instead
- Melanoma: when to do a sentinel node, and when to give adjuvant or neoadjuvant therapy
- Ifosfamide encephalopathy: recognition, risk factors, and the evidence for methylene blue
Oct 9, 2026
- A new myeloma: the three tests to send together, and the four letters of organ damage
- Myeloma kidney: the first 48 hours, what helps and what did not
- First treatment in 2026: four drugs, the high-risk definition, and the blood bank
- A clot on anticoagulation: is it new, and was the drug in the patient?
- A true failure: what to change, and which tests to trust on anticoagulation
Oct 8, 2026
- Liquid biopsy: ask the question first, and order it from clinic
- Guardant360 Liquid and FoundationOne Liquid: reading the report, and what a negative is worth
- Signatera: how it is built, when to draw, and the bladder trial
- Every test by name
- Liquid biopsy by cancer: where it changes treatment, where it only predicts, where it misleads
Oct 7, 2026
- Sickle cell pain crisis: preventing and recognizing acute chest syndrome
- Growth factor after chemotherapy: who, which one, when
- Platelets over a million: reactive or clonal, where the aspirin rule comes from, and why platelets do not cause hyperviscosity
- Iron studies in a sick inpatient: reading the panel, giving iron, finding the blood loss
Oct 6, 2026
- Small cell lung cancer: from 10 months to a positive trial at every step
- Pancreatic cancer: resectability, the new second line, germline testing and PARP inhibitors
- Tumor lysis: who gets rasburicase before chemotherapy, and at what dose
- Ifosfamide inpatient or outpatient, mesna, and what to check each day
- Doxorubicin: the lifetime budget, the label numbers, and the running total before every cycle
This site has a single purpose, which is academic: the education of medical students, residents and fellows. It has no commercial interest, no sponsor and no advertising.